Zura Bio Limited/$ZURA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
- Ticker
- $ZURA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40
- Headquarters
- Henderson, United States
- Website
- zurabio.com
Zura Bio Limited Metrics
BasicAdvanced
$394M
-
-$1.06
0.01
-
Price and volume
Market cap
$394M
Beta
0.01
52-week high
$7.44
52-week low
$3.25
Average daily volume
4.2M
Financial strength
Current ratio
11.291
Quick ratio
11.059
Profitability
EBITDA (TTM)
-101.937
Effective tax rate (TTM)
1.37%
Management effectiveness
Return on assets (TTM)
-37.66%
Return on equity (TTM)
-63.17%
Valuation
Price to book
2.22
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-5.779
Free cash flow yield (TTM)
-17.30%
Free cash flow per share (TTM)
-0.708
Growth
Earnings per share change (TTM)
57.84%
3-year earnings per share growth (CAGR)
-36.49%
What the Analysts think about Zura Bio Limited
Analyst ratings (Buy, Hold, Sell) for Zura Bio Limited stock.
Analyst projections of the future price of Zura Bio Limited stock.
Bulls say / Bears say
TibuSHIELD and TibuSURE are fully enrolled above their targets, with 247 and 91 participants respectively; topline results are expected in Q4 2026 and H1 2027. Those readouts give investors near-term tests of tibulizumab in two different diseases. (Business Wire)
Zura has FDA clearance to start a Phase 2 study of tibulizumab in polymyalgia rheumatica, a condition where many patients remain dependent on long-term steroids. This adds a third potential use for the lead drug in an area with substantial unmet need. (Business Wire)
Zura reported $187.7 million in cash at the end of September and expects it to fund planned operations through at least the end of 2028. That should allow the company to advance its current trials and reach several data milestones without an immediate funding need. (Business Wire)
Tibulizumab has yet to report Phase 2 efficacy results, and Zura has no approved products or product-sales revenue. The investment case therefore depends heavily on upcoming trial readouts, which may not show meaningful benefit. (Business Wire, StockTitan)
The third-quarter net loss widened to $25.8 million from $20.0 million a year earlier as R&D spending increased. Zura has also relied on equity offerings to fund its work, so continued high costs or expanded trials could bring further dilution. (Business Wire, SEC)
Zura is still assessing future development plans for crebankitug and torudokimab rather than advancing them in active clinical trials. This leaves the pipeline less diversified in the near term if tibulizumab fails or disappoints. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Zura Bio Limited Financial Performance
Revenues and expenses
Zura Bio Limited Earnings Performance
Company profitability
Upcoming events
No upcoming events
Zura Bio Limited News
AllArticlesVideos
Funds containing Zura Bio Limited
Fund name | Fund size | $ZURA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.